AMR SVG Icons location

Supporting patient health
is our guiding principle

Explore our history

  1. 2023

    Awarded Vizient's NovaPlus Top Performer Award

    American Regent acquires and then merges with HBT Labs, Inc.

    2022

    Selenious Acid Injection, USP is launched in a single-dose vial

    2021

    Multrys® (trace elements injection*, USP) is launched

    2020

    Tralement® (trace elements injection*, USP), the first FDA-approved trace elements injection is introduced

  2. July 2019

    Launch of the first and only 
    FDA-approved Selenious Acid Injection, USP 

    January 2019

    American Regent, Inc. merges into Luitpold Pharmaceuticals, Inc.  The company name is changed to American Regent.

    2018

    FDA-approval and launch
    of the first preservative free generic Hydroxyprogesterone Caproate Injection, USP

    2017

    American Regent celebrates its 50th Anniversary

  3. 2016

    Launch of ProvayBlue® (methylene blue) Injection, 0.5%, USP*

    *ProvayBlue® is a registered trademark of Provepharm Life Solutions, France

    2013

    Injectafer® (ferric carboxymaltose injection)* is FDA Approved. 

    *Injectafer® is a registered trademark of Vifor (International) Inc., Switzerland

    2009

    Luitpold acquires PharmaForce, Inc., broadening its line of generic, multisource injectables.

  4. 2005

    Sankyo merges with
    Daiichi Pharmaceutical Company, Ltd.
    to become Daiichi-Sankyo Company, Ltd.

    2002

    The name American Regent Laboratories, Inc. was shortened to
    American Regent, Inc.

    2000

    Venofer® (iron sucrose injection, USP), now the #1 selling IV iron in the US,* is approved.
    *Source: IMS, NSP Audit Dollars & Units 3 year MAT ending January 2017

    1996

    American Regent Laboratories introduces Dexferrum® (iron dextran injection, USP).

  5. 1991

    Sankyo, a Japanese pharmaceutical company, acquires Luitpold and its subsidiary, American Regent Laboratories, Inc.

    Mid 1980s

    Luitpold Pharmaceuticals, Inc.
    acquires American Quinine and transforms the name to
    American Regent Laboratories, Inc.

    1967

    A group of dedicated professionals launch our company under the name American Quinine, which provides quality, parenteral products to medical communities within the US and Canada.

Throughout our long history, one thing has been constant—our commitment to ensuring those we serve have the essential medicines they need.

Who We Are

American Regent has a long history. From small beginnings in 1967 as a US-based manufacturer, the company has grown to be one of the leading pharmaceutical companies in the United States. Our growing business is comprised of a mix of branded and generic injectables. For nearly 25 years, we have been the leader in IV iron therapy, supplying the market with the two top-selling brands in the US. For over 40 years, our animal health business has proudly delivered solutions that support the long-term health and well-being of horses and dogs, anchored by two of the leading animal joint health brands.

Our legacy, spanning nearly 60 years, is built on an unwavering commitment to ensuring that the people and animals we serve have the essential medicines they need.

Our Unwavering Purpose

Helping patients live better lives by providing the essential medicines they need is our constant motivation behind everything we do, everyday. To achieve our purpose, our entire organization has dedicated ourselves to our purpose:

Our Mission
To improve human and animal health through the development, manufacturing, and delivery of innovative, accessible, and high-quality sterile injectable products.

Our Vision
Be the leader in supplying and delivering superior quality products that healthcare providers rely on for their patients, with a focus toward fulfilling unmet needs in healthcare by providing industry-leading US manufactured sterile injectables.

Our Core Behaviors

American Regent is on a journey to think, act, and operate with three behaviors that are core to what we stand for:

Be Inclusive & Embrace Diversity: We value people for who they are as individuals, and welcome diverse perspectives in our work, which enables us to achieve more as an organization.

Collaborate & Trust: We treat each other with respect, and build trust through transparency and willingness to listen, which enables us to collaborate simply and productively.

Develop & Grow: We learn, experiment, and take initiative, which enables us to grow together every day,  and strengthen our capabilities.

The power of our employees and their collective efforts helps us achieve our goal of contributing to the health and well-being of patients.

Our Four Operating Principles

Speed counts. Flexibility matters. Quality and reliability are paramount. Because patients should never have to wait for the medications they need.

We are committed to setting a higher standard for responsiveness, reliability, and quality. We continue to make significant investments in expanding and modernizing our US-based manufacturing facilities. We have nearly doubled our capacity, created redundancies across our manufacturing sites, and strengthened our expertise in the development of complex drug products and delivery systems.

Taken together, excellence in these four areas looks like a flexible, fast-moving partner. One that is uniquely positioned to quickly respond to and help mitigate shortages or meet changes in market need. A partner committed to delivering essential medications now and well into the future.

Partner with 
American Regent

American Regent is a leading manufacturer of generic and branded specialty injectables. Given the dynamics of today’s challenging healthcare marketplace...

Learn more

The Latest

  • 2 Jul 2024

    American Regent Introduces Sodium Phosphates Injection, USP; FDA-Approved and “AP” Rated

    Shirley, NY – July 2, 2024:
    American Regent announces the launch and availability of Sodium Phosphates Injection, USP, which is FDA-approved and therapeutically equivalent to Sodium Phosphates.

    Read more

  • 27 Sep 2023

    American Regent Receives 2023 Novaplus Program Excellence Award from Vizient

    Shirley, NY – September 27, 2023:
    American Regent has received a Novaplus Program Excellence Award from Vizient, Inc., the nation’s largest provider-driven health care performance improvement company. The recognition was announced at the 2023 Vizient Connections Summit, held September 18-21 in Las Vegas.

    Read more

Executive Team

Contact Us

Request for Medical Information Request a Grant Investigator Initiated Study Request a Certificate of Analysis Expanded Access Policy
Please choose your preferred method of contact

By clicking Submit, you confirm that you accept our Privacy Policy and that you agree to your personal contact information being used to contact you and added to our database. If at any time you wish your personal information to be removed from the American Regent® database, please submit a message request to corpcommunications@americanregent.com.